The Front Room — a clinical regulatory commons
RSS
← Back to feed

Phase 1 IND Navigator published

FDA released a Phase 1 IND Navigator tool to assist sponsors in preparing and submitting Investigational New Drug applications.

What this means

The FDA's Phase 1 IND Navigator is a resource hub that helps drug developers prepare applications for early-stage human trials of new medicines. Today the agency published updated guidance documents, learning materials, and regulatory references through this online platform. This centralized access to FDA expertise could streamline the process for companies launching first-in-human studies of experimental drugs.

Read original at fda.gov

From the source

The Phase 1 IND Navigator provides the tools, guidances, and regulatory expertise you need to prepare and submit an Investigational New Drug application (IND) to FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).

Contact Us Questions? Contact the Phase 1 Clinical Trials Support Team: Phone: 240-276-9358 Email: Phase1Questions@fda.hhs.gov

Sub-Topic Paragraphs

Guidance Documents

Search for Phase 1-relevant FDA guidance documents by keyword, topic, center, or product.

CDER and CBER Learning Resources

Conference and webinar presentations, online courses, newsletters and podcasts.

Procedures and Policies

Resources from CDER's Manual of Policies and Procedures (MAPPs) and CBER’s Standard Operating Procedures and Policies (SOPPs)

Chemistry, Manufacturing, and Controls

Learn more about new CDER and CBER Chemistry, Manufacturing, and Controls (CMC) Flexibilities for Phase 1 INDs

Federal Regulations and Regulatory References

Learn more about federal regulations that apply to the IND application process

FDA Actions to Accelerate & Modernize Early and Late-Stage Clinical Development

CBER IND Application Resources

Useful information on the development and submission of INDs from FDA's Center for Biologics Evaluation and Research (CBER)

CDER IND Application Resources

Useful information on the development and submission of INDs from FDA's Center for Drug Evaluation and Research (CDER)

FDA Forms

Search FDA's form database for relevant IND submission forms

Paragraph Header Phase 1 Clinical Trials Support Team

Contact Point

Phase1Questions@fda.hhs.gov

240-276-9358

Hours Available

CDER Division of Drug Information

For Latest Updates Follow

Contact Point Twitter

FDA Drug Information

Receive the latest drug information from the US FDA

Reproduced from FDA Drugs (Whats New) · view original · public domain or open-licensed government work

Topic IND submission